Skip to main content

Table 3 Mean daily dose of each csDMARD used in combination with abatacept in the ATTAIN, ASSURE, and ARRIVE studies

From: Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

  Daily dose (mg)
ATTAIN ASSURE ARRIVE
Methotrexate 2.17 3.88 2.60
Hydroxychloroquine 364 323 383
Sulfasalazine 2597 2108 1866
Azathioprine 121 121 124
Leflunomide 18.2 19.9 19.4
  1. No data are available on the dose of individual csDMARDs used in the ACTION study
  2. csDMARD conventional synthetic disease-modifying antirheumatic drug